trade fundament data
upsid target
click enter text
detail increment add model
gilead report financi result thursday close
revenu ep came ahead consensu modest covid
tailwind said would updat guidanc midyear strongli
impli chang
remdesivir rdv natur focu lot new detail given
substanti up-front spend ramp
product factor guidanc tbd
rel launch visibl
rdv approv drug yet model rdv still remain art
scienc moment uncertainti notwithstand build
new model sale product previous carri revenu
revenu contribut start current year peak quickli
slow attrit thereaft assum better diseas control
whether use vaccin therapeut natur
histori diseas also still tbd impact ep slight
dilut accret level accret
diminish beyond period come week/month provid
clariti better inform model assumpt
bodi report full analysi
inform see slide initi updat
perspect remdesivir
addit context compar cover larg cap
biotech us/eu pharma name see slide initi larg cap
add exist us/eu pharma name cover
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday close gilead
report close watch result came consensu revenu ep
said would updat guidanc mid-year result
provid increment addit inform remdesivir rdv drive stock
overal impress report financi result close thursday beat revenu
ep smaller boost covid compani reiter guidanc formal
withdraw describ varieti covid-rel push pull impact financi
wont give updat guidanc result suggest spend could much higher full year basi
given compani heavi push remdesivir rdv rise much prepar remark
provid modest amount new inform rdv beyond alreadi public domain
base case assumpt evolv also bracket worst best case
scenario gener qualit terribl materi natur analyst call
ask inform rdv littl new inform surfac mani question went
unansw commerci model long-term requir exactli full approv
vs approv emerg use set non-covid topic major new updat overal
like remain volatil stock one like great debat head
guidanc updat bear argu rdv alreadi adequ discount current stock
price given strong share price perform ytd bull argu upsid rdv still probabl
under-estim excit factor could continu drive share higher admittedli
difficult know rdv situat unfold come weeks/months/year valu
contribut clariti come public addit clinic trial result
still mani question remain unanswer could lengthi period time includ
competit dynam within space therapeut treat diseas vaccin
prevent diseas well understand natur histori diseas uncertainti
notwithstand includ rdv revenu forecast first time
peak declin gradual thereaft
rate peer perform inform see slide initi updat perspect
remdesivir
addit context compar cover larg cap biotech us/eu pharma name see
slide initi larg cap biotech add exist us/eu pharma name cover
revenu report sale vs estim consensu
ep report non-gaap ep vs estim consensu
biktarvi sale vs consensu descovi sale vs
consensu genvoya sale vs consensu truvada sale
page
vs consensu epclusa sale vs consensu
yescarta sale vs consensu
guidanc updat neither offici confirm suspend
revenu increas ep decreas add rdv revenu
off-set ramp spend chang base model exclud new
contribut rdv minim
revenu estim increas ep estim increas
depend year peak rdv accret ep rel
updat base case model around
ep compound-annual-growth-rate ep compound-annual-growth-rate increas vs prior repres peer
price target increas target repres increas multipl new
ep estim previous lift multipl assumpt rdv approv new
quarter saw benefit covid-rel stock primarili hiv refil earli refil bd focu
remain clinical-stag asset forti seven acquisit guidanc updat
incur addit cost increas spend forti seven acquisit
primarili paus mani on-going clinic trial could lead delay potenti pipelin asset
longer-run
donat exist suppli remdesivir rdv announc previous dose would allow
treatment cours vs dose could treat patient y/e talk ensur patient
 potenti impact revenu expens rdv invest said
prematur say much unfortun addit spend tough know fall
 talk formul rdv either oral inhal focu near term iv
team look might tough oral metabol subq
inhal would like option
page
 niaid studi proport patient analyz interim could impact final find
particular subgroup seem benefit drug could direct quickli
say seen much niaid data yet includ baselin demograph noth
say yet gener primarili look patient requir supplement whether ventil
otherwis still fairli broad
 look nuc could applic milder patient access
ensur ex-u could out-licens ip let other produc exampl believ rdv
potent molecul thu far discuss compani help produc end-
 gener substanti return investor year covid someth
gener similar return time say uniqu differ noth
like mean guidebook rule book
 envis partner product els say commerci drug
long-term suggest could role potenti combin futur way make
rdv effect
 certain rdv lung concentr mind need say believ current
dose adequ hit level need antivir activ
 surpris see activ sever patient say surpris consist
across way rdv look thu far still learn viral kinet say viru
behav differ lot virus
 approv emerg use eua ema open abil actual charg patient
say ye allow remind donat current suppli dose eua first step
 given expertis virolog think recurr possibl quantifi
milder second round end happen could look like even longer period
time interact fda answer second question first say
great work fda respons think fda move quickli
first question realli reli extern model everyon els cant claim
uniqu insight
 upcom moder trial result definit primari endpoint differ
niaid endpoint separ niaid suffici gain full approv say discuss still
on-going term requir full approv term endpoint niaid look time
clinic recoveri point scale gild studi use ordin scale well look day
distribut along scale vs day similar sever trial patient characterist also differ
prep patient descovi covid impact prep switch new patient start
exist treatment larg untouch
page
 talk prep convers better origin target
compani talk long-act agent develop remain confid switch
year end even covid impact longer-act agent includ insti tri formul
long-act inject version bictegravir close enter clinic
 discuss payer mix hiv busi remind usual
drawdown follow regard government channel often see buy impact payer mix
covid creat access challeng cell-bas therapi
hcv us share thank part launch gild author gener ag
stay close touch fda understand covid could impact timelin
 launch virtual basi say hire necessari folk launch
monitor close covid end approach still look launch multipl market
us eu ja note lot team virtual market alreadi
 updat timelin program oa product say timelin
hope remain track oa import see structur improv regulatori guidanc includ
symptom pain improv
 talk broader percept drug industri folk washington back
work rdv exampl say note seem posit chang
rhetor attitud toward drug industri
page
exhibit show compani report actual result vs estim consensu
exhibit gilead result vs wr estim consensu
exhibit summar financi guidanc vs estim
exhibit gilead guidanc vs wr estim old new
page
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement contract oper incom expens outstand margin total profit profit profit incom growth contract oper
page
product revenu hiv ambisom fungal epclusa harvoni sovaldi letairi ranexa vemlidi vosevi yescarta zydelig filgotinib jak ra ipf ww magrolimab blood earli phase total
exhibit wr gilead balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash market securi flow invest activ lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash equival st market properti plant net current term non-curr sharehold liabil sharehold
